Assembly Biosciences reported a net loss of $10.20 million for the second quarter ended June 30, 2025, an improvement from a net loss of $11.15 million in Q2 2024. Collaboration revenue from a related party (Gilead) increased by 13% year-over-year to $9.63 million for Q2 2025.
Research and development expenses were $16.13 million in Q2 2025, a slight 1% decrease year-over-year, while general and administrative expenses remained consistent at $4.59 million. Net cash used in operating activities increased to $40.20 million for the six months ended June 30, 2025.
As of June 30, 2025, Assembly Bio held cash, cash equivalents, and marketable securities totaling $75 million, leading to a disclosure of "substantial doubt about its ability to continue as a going concern" beyond mid-2026. The company also reported interim Phase 1a data for ABI-6250, showing a four-day half-life and dose-dependent elevations of total serum bile acids, indicating NTCP target engagement, though a Grade 2 ALT elevation was observed at the highest single dose.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.